The linear form of PEIpro™ and the manufacturing process developed by Polyplus-transfection® ensure a high, stable and reproducible amount of protonable amines available for transfection while providing a truly deacylated molecule and an extremely low polymer chain length variation. As a result, PEIpro™ is more powerful as it requires less DNA and reagent than other PEIs (Fig 1.) for high protein production yield in both HEK-293 and CHO cells grow in serum free media.
PEIpro™ has been formulated at 1 mg/ml to fit current standards for transfection with PEI. This concentration eases the transfection protocol optimization. Please Contact the Technical Support for any questions about the protocol.

	Fig. 1. PEIpro™ requires less reagent and similar to lower DNA amount than other PEIs. A) Suspension HEK-293 (A) and CHO (B) cells were seeded at 1×106 cells/ml in serum free medium and transfected with PEIpro™, PEI “Max”and L-PEI 25 kDa (Polysciences, Warrington, PA)  resuspended at 1 mg/ml. Luciferase expression was assayed 48 h after transfection using a conventional luciferase assay.

The quality of PEIpro™ is continuously assessed during the manufacturing process with the appropriate control testing (Fig. 2). Systematic lot management and release testing is performed for each lot produced. A standardized transfection assay is performed with a suspension HEK-293 cell line in serum-free media to ensure the reliability and reproducibility of the transfection efficiency and protein yield under conditions that are suitable for biomanufacturing.A full list of QCs is available upon request (Contact the Technical Support).

Fig. 2. PEIpro™ in-process and lot release quality controls.

PEIpro™  is manufactured and formulated using a highly controlled production process (Fig. 2). Moreover, in order to meet or exceed current regulatory guidelines, PEIpro™ is released using advanced quality controls including a specification for a transfection efficiency that guarantees excellent lot to lot consistency (Fig. 3).

Fig. 3. Excellent lot-to-lot protein yield reproducibility using PEIpro™. Suspension HEK-293 cells were seeded at 1×106 cells/ml in serum-free medium and transfected with PEIpro™ following the standard protocol. Luciferase expression was assayed 48 h after transfection using a conventional luciferase assay.

PEIpro™ is free of component of animal-origin.
In addition, Polyplus-transfection^® is ISO 9001 Quality Management System accredited since 2002; this level of certification assures global customers that the supplier has established reliable and effective processes for product development, manufacturing, sales and customer support.
PEIpro™ is tested to ensure complete sterility, absence of mycoplasma and very low level of bacterial endotoxins following pharmacopeia standards. In addition, on request, Polyplus-transfection® can supply fully GMP compliant product delivering the highest quality level reagent and documentation for the production of therapeutic proteins or viral vectors.

Polyplus-transfection^® SA  is the exclusive worldwide licensee of U.S. Patent No. 6,013,240, European Patent No. 0770140, and foreign equivalents, which cover transfection compositions having nucleic acids and a cationic polymer based on polyethylenimine (PEI), and use of this cationic polymer in nucleic acid transfection.
Polyplus-transfection^® sells branded PEI-based transfection reagents under its exclusive license, including the PEIpro™. For PEIpro™ transfection reagent sold by Polyplus-transfection^® and its authorized distributors, Polyplus hereby conveys license rights to the buyer to use the purchased transfection reagents, to the exclusion of human use, to perform stable or transient transfection for research and commercial purposes.
No rights to reverse engineer or resell are conveyed for any purchased transfection reagent. No license rights whatsoever are conveyed for any PEI-based molecules purchased from unauthorized sources for transfection purposes, and Polyplus reserves all rights and remedies relating to such unauthorized purchases.